The Role of the CTLA4 Blockade in the Treatment of Malignant Melanoma

Enhancement of Antitumor Immunity by CTLA-4 Blockade

1996 • 3,585 citations

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1995 • 2,842 citations

CTLA-4 can function as a negative regulator of T cell activation

1994 • 2,107 citations

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

1995 • 2,090 citations

The B7–CD28 superfamily

2002 • 1,646 citations

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

2003 • 1,564 citations

CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL

1995 • 1,212 citations

Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

2001 • 1,033 citations

Natural selection of tumor variants in the generation of “tumor escape” phenotypes

2002 • 1,014 citations

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

1999 • 1,000 citations

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

2005 • 997 citations

CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy

2001 • 964 citations

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.

1996 • 917 citations

Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

2006 • 812 citations

CTLA-4 ligation blocks CD28-dependent T cell activation.

1996 • 787 citations

CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.

1989 • 662 citations

The Interaction Properties of Costimulatory Molecules Revisited

2002 • 640 citations

Toxicities of Immunotherapy for the Practitioner

2015 • 604 citations

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

2005 • 584 citations

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

2005 • 486 citations

PI3K/Akt/mTOR pathway as a target for cancer therapy

2005 • 452 citations

Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma

2004 • 432 citations

CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation

1999 • 412 citations

CTLA-4 Regulates Induction of Anergy In Vivo

2001 • 409 citations

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1997 • 383 citations

CTLA-4: a negative regulator of autoimmune disease.

1996 • 382 citations

Distinct roles of CTLA‐4 and TGF‐β in CD4⁺CD25⁺ regulatory T cell function

2004 • 377 citations

CTLA-4 blockade synergizes with tumor-derived granulocyte– macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma

1998 • 375 citations

Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal Cancer

2005 • 350 citations

Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade

2005 • 331 citations

Characterization of CTLA-4 structure and expression on human T cells.

1993 • 319 citations

CD28, CTLA‐4 and their ligands: who does what and to whom?

2000 • 317 citations

Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine

2001 • 307 citations

CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction

2005 • 293 citations

CTLA-4 Blockade Reverses CD8+ T Cell Tolerance to Tumor by a CD4+ T Cell– and IL-2-Dependent Mechanism

1999 • 287 citations

Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen).

1985 • 285 citations

Developing aptamers into therapeutics

2000 • 278 citations

CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis.

1996 • 232 citations

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy

1999 • 223 citations

Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response.

1995 • 220 citations

CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation.

1996 • 220 citations

An Autoimmune Disease-Associated CTLA-4 Splice Variant Lacking the B7 Binding Domain Signals Negatively in T Cells

2004 • 212 citations

Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.

1997 • 197 citations

Differential expression of CTLA-4 among T cell subsets

2004 • 162 citations

Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma

2006 • 147 citations

B7-1 or B7-2 Is Required to Produce the Lymphoproliferative Phenotype in Mice Lacking Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4)

1999 • 146 citations

Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma

2006 • 141 citations

Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells

2002 • 137 citations

Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.

1998 • 129 citations

Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques

2003 • 128 citations

Suppressive properties of human CD4⁺CD25⁺ regulatory T cells are dependent on CTLA‐4 expression

2004 • 126 citations

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

2004 • 124 citations

CTLA-4 regulates cell cycle progression during a primary immune response

2002 • 122 citations

Polymorphisms in the Cytotoxic T Lymphocyte Antigen-4 Gene Region Confer Susceptibility to Addison’s Disease

2004 • 117 citations

Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens

2003 • 115 citations

Skin Reactions in a Subset of Patients With Stage IV Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen 4 Monoclonal Antibody as a Single Agent

2006 • 111 citations

Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma

2005 • 94 citations

Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer

1998 • 94 citations

Expression of CTLA‐4 by Human Monocytes

2002 • 88 citations

Regulation of Surface and Intracellular Expression of CTLA‐4 on Human Peripheral T Cells

2001 • 87 citations

Synergistic induction of CTLA-4 expression by costimulation with TCR plus CD28 signals mediated by increased transcription and messenger ribonucleic acid stability.

1997 • 87 citations

IFN-gamma regulates murine interferon-inducible T cell alpha chemokine (I-TAC) expression in dendritic cell lines and during experimental autoimmune encephalomyelitis (EAE).

2002 • 87 citations

Antagonistic Roles for CTLA-4 and the Mammalian Target of Rapamycin in the Regulation of Clonal Anergy: Enhanced Cell Cycle Progression Promotes Recall Antigen Responsiveness

2001 • 85 citations

Regulatory T cells and tumor immunity

2005 • 85 citations

Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma

2003 • 83 citations

Suppressor activity of anergic T cells induced by IL‐10‐treated human dendritic cells: association with IL‐2‐ and CTLA‐4‐dependent G₁ arrest of the cell cycle regulated by p27^Kip1

2003 • 79 citations

Treatment of metastatic melanoma with autologous, hapten‐modified melanoma vaccine: Regression of pulmonary metastases

2001 • 71 citations

CD25+CD4+ regulatory T cells exert in vitro suppressive activity independent of CTLA-4

2005 • 71 citations

The paradox of T cell?mediated antitumor immunity in spite of poor clinical outcome in human melanoma

2004 • 70 citations

Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer

2006 • 67 citations

CD28 Regulates the Translation of Bcl-xL via the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Pathway

2005 • 66 citations

Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis

2000 • 65 citations

CTLA4 polymorphisms are associated with vitiligo, in patients with concomitant autoimmune diseases

2005 • 65 citations

Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor

1994 • 55 citations

CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system

2006 • 54 citations

Prevention of renal damage in murine lupus nephritis by CTLA‐4Ig and cyclophosphamide

2004 • 54 citations

Active-specific immunization against melanoma: Is the problem at the receiving end?

2003 • 53 citations

Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma

2005 • 50 citations

Immunoinhibitory DNA Vaccine Protects Against Autoimmune Diabetes Through cDNA Encoding a Selective CTLA-4 (CD152) Ligand

2002 • 49 citations

Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia

2002 • 48 citations

Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays

2006 • 41 citations

Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

2007 • 41 citations

CTLA-4 Differentially Regulates T Cell Responses to Endogenous Tissue Protein Versus Exogenous Immunogen

2002 • 41 citations

CTLA-4−/− Mice Display T Cell-apoptosis Resistance Resembling that Ascribed to Autoimmune-prone Non-obese Diabetic (NOD) Mice

2001 • 39 citations

Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma

2007 • 39 citations

Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010)

2005 • 38 citations

Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma

2006 • 38 citations

A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC)

2006 • 36 citations

Improving Survival in Patients with High-Risk and Metastatic Melanoma

2003 • 33 citations

Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206.

2004 • 33 citations

Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma

2005 • 30 citations

Provision of Granulocyte-Macrophage Colony-Stimulating Factor Converts an Autoimmune Response to a Self-Antigen into an Antitumor Response

2005 • 25 citations

Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study

2007 • 20 citations

CTLA-4 (CD152) and its involvement in autoimmune disease

2005 • 19 citations

Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies

2004 • 18 citations

Surveillance of the Eye and Vision in Clinical Trials of CP-675,206 for Metastatic Melanoma

2007 • 17 citations

A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer

2006 • 15 citations

Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma

2006 • 14 citations

Phase I clinical trials of ticilimumab: Tumor responses are sufficient but not necessary for prolonged survival

2006 • 13 citations

A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma

2004 • 13 citations

CP-675,206 anti-CTLA4 antibody clinical candidate enhances IL-2 production in cancer patient T cells in vitro regardless of tumor type or stage of disease

2004 • 13 citations

Therapy with human monoclonal anti-CTLA-4 antibody, CP-675,206, reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma (MM)

2005 • 12 citations

Differential Requirement for CD28/CTLA-4-CD80/CD86 Interactions in Drug-Induced Type 1 and Type 2 Immune Responses to Trinitrophenyl-Ovalbumin

2005 • 12 citations

Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.

2003 • 12 citations

Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206

2007 • 9 citations

Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumab

2006 • 6 citations

Clearance of monoclonal antibody (mAb) CP-675,206 by therapeutic plasma exchange (TPE) or plasmapheresis

2007 • 6 citations

Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF)

2004 • 6 citations

Immune Modulating Effects of Low Doses of Cyclophosphamide and Keyhole Limpet Hemocyanine on Peripheral Blood Immune Parameters in Patients with Metastatic Renal Cell Carcinoma

1992 • 6 citations

Post-vaccination CTLA-4 expression correlates inversely with survival in patients vaccinated with allogeneic melanoma cell vaccine

2004 • 3 citations

BEAM Versus CEB Conditioning for Autologous Transplantation in Patients with Non-Hodgkin’s Lymphoma and Hodgkin’s Disease: A Single Center Comparative Study of 219 Patients.

2005 • 1 citations

Deleted Work

1955 • 0 citations